Stiris Research Inc. Announces First Site Activated Phase Ib Amyotrophic Lateral Sclerosis Study

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, is pleased to announce the first site activated in a Phase Ib Amyotrophic Lateral Sclerosis (ALS) study.

“We are thrilled to be part of expanding research in this rare disease, and happy to announce the activation of the first site in this ALS clinical trial.  We are extremely proud to support another Sponsor in their effort to bring potential innovative long-term treatment solutions to the niche of ALS.” said Shantal Feltham, President & CEO.

​Amyotrophic lateral sclerosis (ALS), is a rare neurological disease that affects motor neurons—those nerve cells in the brain and spinal cord that control voluntary muscle movement. Voluntary muscles are those we choose to move to produce movements like chewing, walking, and talking. Nearly all cases of ALS are considered sporadic. This means the disease seems to occur at random with no clearly associated risk factors and no family history of the disease. Although family members of people with sporadic ALS are at an increased risk for the disease, the overall risk is very low and most will not develop ALS.